Evaluation of mithramycin in the treatment of anaplastic gliomas

Restricted access

✓ A controlled, prospective, randomized study evaluated the use of mithramycin in the treatment of anaplastic glioma compared to a similar group of patients receiving best conventional care. From a total of 116 patients in the study, 96 were within the valid study group. All patients were operated on, had histological confirmation of anaplastic glioma, and received radiotherapy at the discretion of the principal investigator. Fifty-two patients received mithramycin at a dose of 25 µg/kg/day for 21 days, while 44 patients were in the control group. There was no significant difference in the median survival from time of randomization in those receiving mithramycin (21 weeks) as compared to those not receiving mithramycin (26 weeks). There was no significant difference between the two groups in relation to age distribution, sex, location, diagnosis, tumor characteristics, signs or symptoms, or radiotherapy received. Duration of symptoms correlates positively with survival and was also significantly longer in the control group than in the treated group. This, however, did not account for the failure of mithramycin to be found an effective agent. Although the study was not designed to evaluate the efficacy of radiotherapy, patients who were so treated had a significant improvement in survival. The toxic complications of mithramycin included gastrointestinal symptoms, dermatological involvement, anemia, and liver dysfunction, indicating the need for close supervision.

Article Information

Address reprint requests to: Michael D. Walker, M.D., 22 South Greene Street, Baltimore, Maryland 21201.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    The survival curves of the Valid Study Group are shown; 52 patients receiving mithramycin are compared to 44 control patients.

References

  • 1.

    Batzdorf U: Chemotherapy of glioblastoma multiforme: an appraisal. Bull Los Angeles Neurol Soc 31:1641761966Batzdorf U: Chemotherapy of glioblastoma multiforme: an appraisal. Bull Los Angeles Neurol Soc 31:164–176 1966

  • 2.

    Burdette WJGehan EA: Planning and Analysis of Clinical Studies. Springfield, Ill: Charles C Thomas1970Burdette WJ Gehan EA: Planning and Analysis of Clinical Studies. Springfield Ill: Charles C Thomas 1970

  • 3.

    Edland RWJavid MAnsfield FJ: Glioblastoma multiforme. An analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-fluorouracil. A prospective randomized study of 32 cases. Am J Roentgenol Radium Ther Nucl Med 111:3373421971Edland RW Javid M Ansfield FJ: Glioblastoma multiforme. An analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-fluorouracil. A prospective randomized study of 32 cases. Am J Roentgenol Radium Ther Nucl Med 111:337–342 1971

  • 4.

    Frankel SAGerman WJ: Glioblastoma multiforme. Review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 15:4895031958Frankel SA German WJ: Glioblastoma multiforme. Review of 219 cases with regard to natural history pathology diagnostic methods and treatment. J Neurosurg 15:489–503 1958

  • 5.

    Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:2032231965Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223 1965

  • 6.

    Kaplan ELMeier P: Nonparametric estimation from incomplete observations. J Amer Stat Assoc 53:4574811958Kaplan EL Meier P: Nonparametric estimation from incomplete observations. J Amer Stat Assoc 53:457–481 1958

  • 7.

    Kennedy BJBrown JHYarbro JW: Mithramycin (NSC-24559) therapy for primary glioblastomas. Cancer Chemother Rep 48:59631965Kennedy BJ Brown JH Yarbro JW: Mithramycin (NSC-24559) therapy for primary glioblastomas. Cancer Chemother Rep 48:59–63 1965

  • 8.

    Kennedy BJSandberg-Wollheim MLoken Met al: Studies with tritiated mithramycin in C3H mice. Cancer Res 27:153415381967Kennedy BJ Sandberg-Wollheim M Loken M et al: Studies with tritiated mithramycin in C3H mice. Cancer Res 27:1534–1538 1967

  • 9.

    Kume FMaruyama SD'Agostino ANet al: Nucleolar change produced by mithramycin in rat hepatic cell. Exp Mol Pathol 6:2542601967Kume F Maruyama S D'Agostino AN et al: Nucleolar change produced by mithramycin in rat hepatic cell. Exp Mol Pathol 6:254–260 1967

  • 10.

    Kurland LTMyrianthopoulos NCLessell S: Epidemiologic and genetic considerations of intracranial neoplasms in Field WSSharkey PC (eds): The Biology and Treatment of Intracranial Tumors. Springfield, Ill: Charles C Thomas1962Kurland LT Myrianthopoulos NC Lessell S: Epidemiologic and genetic considerations of intracranial neoplasms in Field WS Sharkey PC (eds): The Biology and Treatment of Intracranial Tumors. Springfield Ill: Charles C Thomas 1962

  • 11.

    Leventhal CMWalker MD: Chemotherapy of Malignant Glioma: A Collaborative Study. Amsterdam: Excerpta Medica International Congress Series no. 1931969 p 33Leventhal CM Walker MD: Chemotherapy of Malignant Glioma: A Collaborative Study. Amsterdam: Excerpta Medica International Congress Series no. 193 1969 p 33

  • 12.

    Livingston RBCarter SK: Single Agents in Cancer Chemotherapy. New York: Plenum Press1970Livingston RB Carter SK: Single Agents in Cancer Chemotherapy. New York: Plenum Press 1970

  • 13.

    Martin BFWalker DGRansohoff J: Preliminary clinical and laboratory investigation of a chemotherapeutic agent in the treatment of brain tumors. J Natl Med Assoc 59:3233261967Martin BF Walker DG Ransohoff J: Preliminary clinical and laboratory investigation of a chemotherapeutic agent in the treatment of brain tumors. J Natl Med Assoc 59:323–326 1967

  • 14.

    Preliminary Report: Third National Cancer Survey. 1969 Incidence. Prepared by Biometry Branch National Cancer Institute National Institutes of Health Bethesda Maryland. DHEW Publication (NIH) 72–128.Preliminary Report: Third National Cancer Survey. 1969 Incidence. Prepared by Biometry Branch National Cancer Institute National Institutes of Health Bethesda Maryland. DHEW Publication (NIH) 72–128.

  • 15.

    Rall DPZubrod CG: Mechanisms of drug absorption and secretion. Passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2:1091281962Rall DP Zubrod CG: Mechanisms of drug absorption and secretion. Passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2:109–128 1962

  • 16.

    Ransohoff JMartin BFMedreck TJet al: Preliminary clinical study of mithramycin (NSC-24559) in primary tumors of the nervous system. Cancer Chemother Rep 49:51571965Ransohoff J Martin BF Medreck TJ et al: Preliminary clinical study of mithramycin (NSC-24559) in primary tumors of the nervous system. Cancer Chemother Rep 49:51–57 1965

  • 17.

    Rao KVCullen WPSobin BA: A new antibiotic with antitumor properties. Antibiot Chemother 12:1821861962Rao KV Cullen WP Sobin BA: A new antibiotic with antitumor properties. Antibiot Chemother 12:182–186 1962

  • 18.

    Ream NWPerlia CPWolter Jet al: Mithramycin therapy in disseminated germinal testicular cancer. JAMA 204:103010361968Ream NW Perlia CP Wolter J et al: Mithramycin therapy in disseminated germinal testicular cancer. JAMA 204:1030–1036 1968

  • 19.

    Roth JGElvidge AR: Glioblastoma multiforme: a clinical survey. J Neurosurg 17:7367501960Roth JG Elvidge AR: Glioblastoma multiforme: a clinical survey. J Neurosurg 17:736–750 1960

  • 20.

    Russell DSRubinstein LJ: Pathology of Tumours of the Nervous System ed 3. London: Edward Arnold1970Russell DS Rubinstein LJ: Pathology of Tumours of the Nervous System ed 3. London: Edward Arnold 1970

  • 21.

    Sandberg-Wollheim MYarbro JWKennedy BJ: Effect of mithramycin on hela cells. Cancer 21:22251968Sandberg-Wollheim M Yarbro JW Kennedy BJ: Effect of mithramycin on hela cells. Cancer 21:22–25 1968

  • 22.

    Shapiro WRAusman JIRall DP: Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis (2-chloroethyl)-1-nitrosourea, cyclophosphamide, mithramycin, and methotrexate. Cancer Res 30:240124131970Shapiro WR Ausman JI Rall DP: Studies on the chemotherapy of experimental brain tumors: evaluation of 13-bis (2-chloroethyl)-1-nitrosourea cyclophosphamide mithramycin and methotrexate. Cancer Res 30:2401–2413 1970

  • 23.

    Snedecor GCochran WG: Statistical Methodsed 6. Ames, Iowa: Iowa State University Press1967 pp 215220Snedecor G Cochran WG: Statistical Methods ed 6. Ames Iowa: Iowa State University Press 1967 pp 215–220

  • 24.

    Systematized Nomenclature of Pathology. Chicago: College of American Pathologists1965Systematized Nomenclature of Pathology. Chicago: College of American Pathologists 1965

  • 25.

    Tumors of the Central Nervous System. 14th Annual Clinical Conference of the Ontario Cancer Treatment and Research Foundation and the Hamilton Clinic. OntarioNovember 3, 1967Tumors of the Central Nervous System. 14th Annual Clinical Conference of the Ontario Cancer Treatment and Research Foundation and the Hamilton Clinic. Ontario November 3 1967

  • 26.

    Walker MD: Brain and peripheral nervous system tumors in Holland JFFrei E 3rd (eds): Cancer Medicine. Philadelphia: Lea & Febiger1973 pp 13851407Walker MD: Brain and peripheral nervous system tumors in Holland JF Frei E 3rd (eds): Cancer Medicine. Philadelphia: Lea & Febiger 1973 pp 1385–1407

  • 27.

    Walker MDCarlton FJOwens E: The distribution of tritium after administration of mithramycin-H3 to normal and brain tumor bearing monkeys. Fed Proc 27:7601968 (Abstract 3054)Walker MD Carlton FJ Owens E: The distribution of tritium after administration of mithramycin-H3 to normal and brain tumor bearing monkeys. Fed Proc 27:760 1968 (Abstract 3054)

  • 28.

    Wilson CBHoshino T: Current trends in the chemotherapy of brain tumors with special reference to glioblastomas. J Neurosurg 31:5896031969Wilson CB Hoshino T: Current trends in the chemotherapy of brain tumors with special reference to glioblastomas. J Neurosurg 31:589–603 1969

  • 29.

    Woodhall BHall KMahaley S Jret al: Chemotherapy of brain cancer: experimental and clinical studies in localized hypothermic cerebral perfusion. Ann Surg 150:6406521959Woodhall B Hall K Mahaley S Jr et al: Chemotherapy of brain cancer: experimental and clinical studies in localized hypothermic cerebral perfusion. Ann Surg 150:640–652 1959

  • 30.

    Yarbro JWKennedy BJBarnum CP: Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res 26:36391966Yarbro JW Kennedy BJ Barnum CP: Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res 26:36–39 1966

TrendMD

Cited By

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 43 43 4
Full Text Views 1884 1884 0
PDF Downloads 89 89 0
EPUB Downloads 0 0 0

PubMed

Google Scholar